Lipokinetix®
Manufacturer:
Syntrax Innovations, Inc.
Uses: Dietary Supplement
More Information
 |
| Lipokinetix |
The U.S. Food and Drug Administration warns consumers not to use Lipokinetix, touted a "dietary supplement" by Syntrax Innovations, Inc., since FDA has received at least six reports of users who developed Liver Injury or Liver Failure. The product has been claimed to produce weight loss by "mimicking exercise" and causing "an increased metabolic rate."
Lipokinetix is marketed for weight loss. It contains the ingredients Norephedrine (also known as Phenylpropanolamine or PPA), caffeine, yohimbine, diiodothyronine, and sodium Usniate. The injuries reported to FDA occurred in persons between 20 and 32 years of age. No apparent cause of Liver Injury was identified in these reports other than use of Lipokinetix. Liver Injury develops between 2 weeks and 3 months of Lipokinetix use. Being an herbal preparation, the responsibility for the safety of the medication and accuracy of information (including informing patients of risk) falls completely on the sponsor, Syntrax.
Side Effects
- Liver Toxicity
- Hepatitis
- Death
Resources
For more information:
Pharmaceutical Litigation
Prescription
Injury FAQs
Pharmaceutical Legal Glossary
|
